N-Acetyl Selank Amidate

Description

N-Acetyl Selank Amidate is a modified version of the nootropic peptide Selank, engineered for enhanced stability and improved blood-brain barrier permeability. It exhibits anxiolytic and cognitive-enhancing properties similar to its parent compound.

Overview

N-Acetyl Selank Amidate is a synthetic heptapeptide derived from Selank, which itself is an analog of the naturally occurring human tetrapeptide tuftsin. The modifications in N-Acetyl Selank Amidate, including an acetyl group at the N-terminus and an amide group at the C-terminus, as well as a Pro-Gly-Pro fragment, are designed to enhance its stability and improve its ability to traverse the blood-brain barrier, thereby increasing its efficacy within the central nervous system. While research specifically on N-Acetyl Selank Amidate is limited, its mechanisms and effects are extrapolated from extensive studies on Selank. Selank has demonstrated significant anxiolytic properties, showing comparable effectiveness to established anti-anxiety medications in clinical trials for generalized anxiety disorder (GAD). Beyond anxiety reduction, Selank also exhibits nootropic effects, contributing to cognitive enhancement, particularly in individuals experiencing anxiety-related conditions. It has been observed to improve memory and attention, and may mitigate some side effects of conventional anxiolytics. Furthermore, Selank has shown immunomodulatory effects, especially in contexts of stress and mood disorders. Research indicates its potential to balance cytokine levels, suggesting a role in immune regulation under stressful conditions. The peptide's interaction with various neurotransmitter systems, including GABA, serotonin, and enkephalins, as well as its ability to upregulate BDNF, underpins its diverse therapeutic potential in managing neurological and psychological states.

Mechanism of Action

This peptide crosses the blood-brain barrier and influences the central nervous system by modulating levels of brain-derived neurotrophic factor (BDNF), as well as interacting with opioid, serotonergic, and GABAergic signaling pathways. This activity contributes to its anxiolytic, stress-reducing, and nootropic effects.

Benefits

• •Reduces anxiety and stress
• •Enhances cognitive function
• •Improves mood regulation
• •Modulates immune responses
• •Supports neuronal growth and survival
• •May improve memory retention

Dosing Notes

Dosing protocols for N-Acetyl Selank Amidate are based on research into its parent compound, Selank. A typical intranasal regimen involves administering 600-900 mcg daily, divided into 2-3 applications, for a period of up to 14 days. Following this, a washout period of 1 to 3 weeks is recommended to prevent potential receptor desensitization. In some clinical studies, Selank has been administered at higher doses, up to 2700 mcg daily, for similar durations. Researchers should closely monitor for adverse reactions and discontinue use if any negative effects are observed.

Reported Side Effects

• •Nasal dryness
• •Throat irritation
• •Hypersensitivity
• •Bacterial contamination (with nasal spray)
• •Pain at injection site
• •Induration at injection site
• •Bleeding at injection site
• •Redness at injection site
• •Swelling at injection site

Safety Notes

Specific safety data for N-Acetyl Selank Amidate is currently insufficient. However, studies on intranasal Selank suggest good tolerability for short-term use, typically up to one month. Minor local side effects such as nasal dryness, throat irritation, or hypersensitivity may occur with intranasal administration. If administered via subcutaneous injection, localized reactions like pain, redness, or swelling at the injection site are possible. The long-term safety profile and potential for GABAergic system desensitization with prolonged use of Selank or its derivatives are areas requiring further investigation. Nasal evidence review (2026-10-25): no qualifying direct intranasal study was verified for this exact compound. Evidence for a parent peptide, another terminal modification, or a similarly named molecule must not be transferred. The previous nasal indicator was withdrawn; this is not proof that no unpublished study exists.

Scientific References